Storia in 1 fonti

HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times

The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver cancer drug Rivoceranib...

Raccontata da

koreatimes.co.kr

Timeline cronologica

mercoledì 15 luglio 2026·koreatimes.co.kr
HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times
The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver cancer drug Rivoceranib...